SS-31
Elamipretide
SS-31 is a modified tetrapeptide investigated for interactions with mitochondrial cardiolipin. Its chemistry includes D-arginine and dimethyltyrosine, so a standard-residue sequence would be incomplete.
Reviewed September 2026
- Residues
- 4. verified: 4 residues, including D-Arg and noncanonical dimethyltyrosine.
- Average mass
- 639.8 Da. verified: Reference form: SS-31/elamipretide reference D-Arg–2,6-dimethyl-Tyr–Lys–Phe-NH2; peptide moiety, excluding acetate or chloride.; formula C32H49N9O5. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 4 |
|---|---|
| Average mass | 639.8 Da |
| pI | Not established |
| Aliases | Elamipretide |
|---|---|
| Research area | Cellular and longevity |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
SS-31/elamipretide reference D-Arg–2,6-dimethyl-Tyr–Lys–Phe-NH2; peptide moiety, excluding acetate or chloride. Reference only, not a sold-lot measurement.
- Residues: 4 (verified). 4 residues, including D-Arg and noncanonical dimethyltyrosine. Residues source 1 Residues source 2
- Average mass: 639.8 Da (verified). Reference form: SS-31/elamipretide reference D-Arg–2,6-dimethyl-Tyr–Lys–Phe-NH2; peptide moiety, excluding acetate or chloride.; formula C32H49N9O5. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Non-standard peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: SS-31. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About SS-31
Identity and context
The primary mechanistic study specifies D-Arg-dimethylTyr-Lys-Phe-NH2. The D configuration, substituted aromatic residue and terminal amide are required to describe that structure. SS-31 is distinct from the mitochondria-derived peptide MOTS-c.
Reference classification
Non-standard peptide. The linked catalogue product is SS-31. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Check stereochemistry and dimethyltyrosine explicitly in the analytical specification. A mass or composition calculated after replacing the non-standard residue with ordinary tyrosine would be wrong.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | The investigators used cardiolipin-containing membranes, spectroscopy and mitochondrial preparations. They reported interactions with cardiolipin and changes in cytochrome-c-related electron transport and ATP synthesis. These experiments support a specific mechanistic account within those systems. | Source context |
| What cannot be inferred | A mitochondrial assay cannot establish general rejuvenation or improved energy in people. This reference does not assess present marketing authorization, and it does not establish equivalence between any licensed preparation and the listed research product. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complexPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.